PQ Bypass Inc, launched novel fully-percutaneous femoral-popliteal bypass device. The Detour system is considered to be the world’s first bypass device used for treating very long and complex blockages in the Superficial Femoral Artery (SFA).
The Detour System is designed for the treatment of patients, who are not in a position to conduct their daily living activities, patients who are unable to enjoy their liberties of free mobility due to advanced symptomology, severe lesion morphology, and multiple co-morbidities.
Revascularisation emerges as imperative to mitigate the ongoing deterioration and to prevent amputation, once PAD advances to debilitating claudication or tissue loss. If left untreated, it may cause functional deterioration, major adverse limb events, and sometimes even causing death in patients.
US Food and Drug Administration (FDA) grants Breakthrough Device Designation for the Device for the treatment of Extremely Long and Complex superficial femoral artery Lesions.
According to the US Centers for Disease Control and Prevention (CDC), approximately 18 million people in the United States suffer from PAD, a common circulatory problem in which narrowed arteries reduce blood flow to the limbs. Estimates suggest that anywhere from 12 to 20 percent of individuals over the age of 60 are living with PAD.